...

Module

Expert Analysis: How Do Recent Data Impact Practical Management of Patients With GBM?

Source: Current Research Directions in Glioblastoma Multiforme: Evolutions in Targeted Therapy

Expert Analysis: How Do Recent Data Impact Practical Management of Patients With GBM?


Program Director: James J. Vredenburgh, MD

Faculty:

Henry S. Friedman, MDPatrick Y. Wen, MD
  • Henry S. Friedman, MD
  • Patrick Y. Wen, MD

CREDIT INFORMATION

Release Date: January 14, 2009

Expiration Date: January 13, 2010


Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Status: The activity is not currently available for credit.

Begin the Module

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the current National Comprehensive Cancer Network guidelines for treatment for glioblastoma multiforme
  • Describe the roles of bevacizumab and temozolomide in treating patients with glioblastoma multiforme
  • Cite the challenges in incorporating new agents in the newly diagnosed setting and in combining these novel agents for glioblastoma multiforme
  • Explain the impact of genetic heterogeneity on the selection of targeted therapy for glioblastoma multiforme

Topics covered include:

  • Latest National Comprehensive Cancer Network Guidelines for Treating Patients With GBM
  • Clinical Trials in Recurrent GBM in the Bevacizumab Era
  • Other Antiangiogenic Agents for Treatment of GBM
  • The Role of Temozolomide in Treating Patients With Glioblastoma
  • Incorporating New Agents in the Newly Diagnosed Setting
  • Combining Novel Agents
  • Convection-Enhanced Delivery in the Era of Antiangiogenesis
  • Impact of Genetic Heterogeneity on Selection of Targeted Therapy for GBM
  • Treatment of Unmethylated MGMT Promoter Tumors
  • Summary
Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.